生技產業兩階段研發效率分析

Two-Stage R&D Efficiency Analysis of the Biotechnology Industry

張捷軍(Chieh-Chun Chang)；張哲維(Che-Wei Chang)；洪秀婉(Shiu-Wan Hung)；簡俊豪(Jyun-Hao Jian)；張彥文(Yen-Wen Chang)

行動者網絡 ； 生技產業 ； 運營表現 ； 資料包絡分析法 ； Actor-Network ； Biotechnology Industry ； Operation Performance ； Data Envelopment Analysis

中原企管評論

21卷1期（2023 / 04 / 01）

89 - 111

繁體中文;英文

全球生物科技研發得耗費龐大的時間與資金，因此如何提高研發效率，是本研究進一步探討的主因。研究根據先前學者分析構建了兩階段網絡模型，並透過行動者網絡理論觀點分別加入產學合作密度及外部法人投資，進一步探討生物科技研發效率。接著對全球排名前33家生技企業進行分析，根據其相關效率值給予建議，並運用管理決策矩陣得知生技企業應藉由專利技術合作運用。研究結果發現，在第一階段技術創造必須注意對於研發的投入與產學合作的密度；而第二階段價值創造則是必須仰賴外部法人投資及內部資源投入相互運行串聯及整合，以創造更大營收及提高總市值。就區域別而言，歐洲之技術創造表現最佳，美洲為價值創造效率較佳，亞太地區則是兩者均衡發展。最後，研究發現學術及法人投資機構皆為影響生技產業研發的重要關鍵，因此不容忽視。

The development of global biotechnology R&D has consumed enormous time and money. This study is mainly focus on further explore how to increase the efficiency of research and development. In this study, a two-stage network model was constructed based on previous scholars' analysis, and the industry-university cooperation density and external corporate investment were added respectively through the Actor-Network Theory to further explore the efficiency of biotechnology research and development. Then, we analyzed the top 33 biotech companies in the world and found out their relative efficiency values. Lastly, Using the Management Decision Matrix to learn that biotechnology companies reinforce the shortcomings in the first phase of research and development through patent and technology collaboration reinforcement. In addition, in the second stage, investors should be informed more about company operations and research and development projects, thereby increasing the relative value of the company's second phase. The results of the study found that most manufacturers did not fully invest in technology creation in the first stage, which led to a significant drop in the overall efficiency value. Therefore, attention must be paid to R&D investment and the density of industry-university cooperation; in the second stage, value creation must rely on external legal person investment and internal resources. Therefore, we should actively connect and integrate all parties, use inseparable cooperation and division of labor, and reduce costs to create greater revenue and increase total market value. In terms of regions, Europe performed best in technology creation, the Americas performed better in value creation efficiency, and the Asia-Pacific region developed in a balanced manner. Finally, the study found that both academic and corporate investment institutions are important factors that affect the research and development of the biotechnology industry, so they cannot be ignored.

1. 張淑清,呂欣樺(2015)。研發支出與管理團隊特性對公司績效之影響。會計學報，6(1)，1-34。
   連結：
2. Genet 觀點，2021，「【中港生技】九天生物與美國 BioMarin 製藥公司共同宣佈達成全球戰略合作，為心血管疾病開發創新基因療法」，https://reurl.cc/mZe3KG，搜尋日期：2023 年 1 月 15 日。
3. Genet 觀點，2020，「《數位醫療 AI》吉利德、拜爾都搶入 AI 研發！BioMarin 與 Deep Genomics 攜手，以 AI 平台開發寡核苷酸藥物」，https://reurl.cc/NGzRMm，搜尋日期：2023 年 1 月 15 日。
4. Genet 觀點，2018，「英國脫歐效應正式登場!一家生技公司決定暫停於英國的臨床試驗」，https://reurl.cc/RONqWg，搜尋日期：2023 年 1 月 14 日。
5. AUTM,BIO.(2017).,未出版
6. Bhattacharya, S.,Hirmand, M.,Phung, D.,van Os, S.(2015).Development of enzalutamide for metastatic castration‐resistant prostate cancer.Annals of the New York Academy of Sciences,1358(1),13-27.
7. Bosi, F.,Mazzocchi, E.,Jatro, I.,Dal Corso, F.,Piccolroaz, A.,Deseri, L.,Bigoni, D.,Cocquio, A.,Cova, A.,Odorizzi, S.(2013).A collaborative project between industry and academia to enhance Engineering Education at graduate and PhD level in ceramic technology.International Journal of Engineering Education,29(6),1362-1370.
8. Breyer, C.,Birkner, C.,Meiss, J.,Goldschmidt, J. C.,Riede, M.(2013).A top-down analysis: Determining photovoltaics R&D investments from patent analysis and R&D headcount.Energy Policy,62,1570-1580.
9. Callon, M.(1984).Some elements of a sociology of translation: domestication of the scallops and the fishermen of St Brieuc Bay.The Sociological Review,32(1_suppl),196-233.
10. Chen, P. C.,Hung, S. W.(2016).An actor-network perspective on evaluating the R&D linking efficiency of innovation ecosystems.Technological Forecasting and Social Change,112,303-312.
11. Compustat., 2017, Standard & Poor’s Global Market Intelligence, https://www.marketplace.spglobal.com/en/datasets. Accessed January 14, 2023.
12. Dyer, O.(2018).Trump signs bill to give patients right to try drugs.BMJ: British Medical Journal,361
13. FIERCE Pharma, 2020, Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way, https://reurl.cc/zrmNqN. Accessed January 15, 2023.
14. Gans, J. S.,Stern, S.(2003).The product market and the market for “ideas”: Commercialization strategies for technology entrepreneurs.Research Policy,32(2),333-350.
15. Grand View Research., 2022, Global Bioprocess Technology Market Research Report -Industry Analysis, Size, Share, Growth, Trends and Forecast 2022 to 2028, https://reurl.cc/NG7D0x. Accessed January 14, 2023.
16. Keupp, M. M.(2011).How do foreign R&D units in China manage their Chinese R&D staff? An empirical exploration.International Journal of Technology Management,56(1),73-91.
17. Latour, B(1999).On recalling ANT.The Sociological Review,47(1_suppl),15-25.
18. Law, J.(1992).Notes on the theory of the actor-network: Ordering, strategy, and heterogeneity.Systems practice,5(4),379-393.
19. Lee, S.,Yoon, B.,Park, Y.(2009).An approach to discovering new technology opportunities: Keyword-based patent map approach.Technovation,29(6-7),481-497.
20. Lee, Y. S.(1996).‘Technology transfer’and the research university: A search for the boundaries of university-industry collaboration.Research Policy,25(6),843-863.
21. Lo, Y. C.,Rensi, S. E.,Torng, W.,Altman, R. B.(2018).Machine learning in chemoinformatics and drug discovery.Drug Discovery Today,23(8),1538-1546.
22. Merrifield, T.(2006).Optimizing R&D staff integration.Research-Technology Management,49(4),11-14.
23. NS HEALTHCARE., 2022, Roche secures FDA approval for Lunsumio for R/R follicular lymphoma, https://reurl.cc/063WEA. Accessed January 14, 2023.
24. Pazderka, B.(1999).Patent protection and pharmaceutical R&D spending in Canada.Canadian Public Policy/Analyse de Politiques,25(1),29-46.
25. Ran, C.,Song, K.,Yang, L.(2020).An improved solution for partner selection of industry-university cooperation.Technology Analysis & Strategic Management,32(12),1478-1493.
26. Santoro, M. D.(2000).Success breeds success: The linkage between relationship intensity and tangible outcomes in industry–university collaborative ventures.The Journal of High Technology Management Research,11(2),255-273.
27. Scannell, J. W.,Blanckley, A.,Boldon, H.,Warrington, B.(2012).Diagnosing the decline in pharmaceutical R&D efficiency.Nature reviews Drug discovery,11(3),191-200.
28. Shin, K.,Kim, S. J.,Park, G.(2016).How does the partner type in R&D alliances impact technological innovation performance? A study on the Korean biotechnology industry.Asia Pacific Journal of Management,33(1),141-164.
29. Singh, R,Mathiassen, L,Mishra, A.(2015).Organizational path constitution in technological innovation: Evidence from rural telehealth.Mis Quarterly,39(3),643-665.
30. Sueyoshi, T.,Goto, M.(2009).Methodological comparison between DEA (data envelopment analysis) and DEA–DA (discriminant analysis) from the perspective of bankruptcy assessment.European Journal of Operational Research,199(2),561-575.
31. Thayer, A.(2002).Bristol-Myers cuts R&D staff.Chemical & Engineering News,80(43),10-10.
32. Tone, K.,Tsutsui, M.(2009).Network DEA: A slacks-based measure approach.European Journal of Operational Research,197(1),243-252.
33. Van de Vrande, V.,Vanhaverbeke, W.,Duysters, G.(2011).Technology in‐sourcing and the creation of pioneering technologies.Journal of Product Innovation Management,28(6),974-987.
34. Yu, C.,Zhang, Z.,Lin, C.,Wu, Y. J.(2017).Knowledge creation process and sustainable competitive advantage: The role of technological innovation capabilities.Sustainability,9(12),2280.
35. Zerhouni, E. A.(2005).US biomedical research: basic, translational, and clinical sciences.Jama,294(11),1352-1358.
36. 王秀貞,丁慧平,胡毅(2017)。基於 DEA 方法的我國中小企業融資效率評價。系統工程理論與實踐，37(4)，865-874。
37. 李晶潔(2018)。基於 DEA 方法的企業環境行為評價指標研究。科技和產業，18(10)，60-64。
38. 姜昭安,陳殷哲(2014)。研發人員心理資本與工作投入之關連性研究。全球商業經營管理學報，6，15-26。
39. 洪進,余文濤,汪凱(2010)。基於“行動者網絡理論”的中國生物製藥產業技術的演化和治理研究。中國科技論壇，11，55-61。
40. 國家衛生研究院，2019，「共同攜手推動台灣精準醫療─本院與羅氏集團簽訂合作備忘錄」，https://reurl.cc/kq6oXx，搜尋日期：2023 年 1 月 14 日。
41. 張宏帆(2010)。產學合作與創新績效相關因素的關聯性。中華管理學報，11(2)，31-44。
42. 許光華(2013)。產學合作發展方向之研析。朝陽學報，18，1-16。
43. 劉宣,王小依(2013)。行動者網絡理論在人文地理領域應用研究述評。地理科學進展，32(7)，1139-1147。
44. 劉建國(2014)。基於行動者網絡理論的智能交通產業標準化戰略研究。中國科技論壇，2，52-56。